JP7211952B2 - ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療 - Google Patents
ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療 Download PDFInfo
- Publication number
- JP7211952B2 JP7211952B2 JP2019536507A JP2019536507A JP7211952B2 JP 7211952 B2 JP7211952 B2 JP 7211952B2 JP 2019536507 A JP2019536507 A JP 2019536507A JP 2019536507 A JP2019536507 A JP 2019536507A JP 7211952 B2 JP7211952 B2 JP 7211952B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- netrin
- sequence
- nos
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022151769A JP2022176250A (ja) | 2017-01-05 | 2022-09-22 | ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305014 | 2017-01-05 | ||
| EP17305014.7 | 2017-01-05 | ||
| PCT/EP2018/050289 WO2018127570A1 (en) | 2017-01-05 | 2018-01-05 | Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022151769A Division JP2022176250A (ja) | 2017-01-05 | 2022-09-22 | ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503359A JP2020503359A (ja) | 2020-01-30 |
| JP2020503359A5 JP2020503359A5 (cg-RX-API-DMAC7.html) | 2022-05-20 |
| JP7211952B2 true JP7211952B2 (ja) | 2023-01-24 |
Family
ID=57838304
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536507A Active JP7211952B2 (ja) | 2017-01-05 | 2018-01-05 | ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療 |
| JP2022151769A Pending JP2022176250A (ja) | 2017-01-05 | 2022-09-22 | ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022151769A Pending JP2022176250A (ja) | 2017-01-05 | 2022-09-22 | ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12162932B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3565837B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7211952B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102679324B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110291105B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018205730B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3048347A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA039433B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL267775B1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018127570A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022176250A (ja) * | 2017-01-05 | 2022-11-25 | ネトリス ファーマ | ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024001308A (es) * | 2021-07-27 | 2024-05-23 | Netris Pharma | Deteccion de netrina-1, prueba complementaria y terapia basada en radiaciones. |
| CA3246346A1 (en) * | 2022-03-29 | 2023-10-05 | Netris Pharma | NEW MCL-1 INHIBITOR AND COMBINATION OF MCL-1 AND A BH3 MIMETIC, SUCH AS A BCL-2 INHIBITOR |
| WO2024095723A1 (ja) | 2022-11-02 | 2024-05-10 | シチズン・システムズ株式会社 | プリンタ |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015104360A1 (en) | 2014-01-10 | 2015-07-16 | Netris Pharma | Novel anti-netrin-1 antibody |
| WO2016197204A1 (en) | 2015-06-11 | 2016-12-15 | Bionomics Limited | Pharmaceutical combination and uses thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| ES2601352T3 (es) | 2006-02-28 | 2017-02-14 | Centre National De La Recherche Scientifique (Cnrs) | Cribado para compuestos anti-cáncer usando actividad de netrina-1 |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| EP2609430A1 (en) | 2010-08-26 | 2013-07-03 | F.Hoffmann-La Roche Ag | Recombinant fc-fusion protein of the fifth fibronectin type iii domain of dcc |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014002353B1 (pt) | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| EP2708231A1 (en) | 2012-09-12 | 2014-03-19 | Netris Pharma | Combined treatment with netrin-1 interfering drug and chemotherapeutic drug |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| UA122479C2 (uk) * | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| CN104083762A (zh) * | 2014-06-27 | 2014-10-08 | 中国科学院生物物理研究所 | 用于阻断Netrin-1与CD146之间的相互作用的试剂及其肿瘤治疗用途 |
| EP3565837B1 (en) | 2017-01-05 | 2024-04-10 | Netris Pharma | Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs |
-
2018
- 2018-01-05 EP EP18701254.7A patent/EP3565837B1/en active Active
- 2018-01-05 EA EA201991302A patent/EA039433B1/ru unknown
- 2018-01-05 KR KR1020197019645A patent/KR102679324B1/ko active Active
- 2018-01-05 CN CN201880006141.0A patent/CN110291105B/zh active Active
- 2018-01-05 WO PCT/EP2018/050289 patent/WO2018127570A1/en not_active Ceased
- 2018-01-05 US US16/476,239 patent/US12162932B2/en active Active
- 2018-01-05 CA CA3048347A patent/CA3048347A1/en active Pending
- 2018-01-05 AU AU2018205730A patent/AU2018205730B2/en active Active
- 2018-01-05 IL IL267775A patent/IL267775B1/en unknown
- 2018-01-05 JP JP2019536507A patent/JP7211952B2/ja active Active
-
2022
- 2022-09-22 JP JP2022151769A patent/JP2022176250A/ja active Pending
-
2024
- 2024-09-16 US US18/886,180 patent/US20250002572A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015104360A1 (en) | 2014-01-10 | 2015-07-16 | Netris Pharma | Novel anti-netrin-1 antibody |
| WO2016197204A1 (en) | 2015-06-11 | 2016-12-15 | Bionomics Limited | Pharmaceutical combination and uses thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022176250A (ja) * | 2017-01-05 | 2022-11-25 | ネトリス ファーマ | ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190101991A (ko) | 2019-09-02 |
| EP3565837C0 (en) | 2024-04-10 |
| EP3565837B1 (en) | 2024-04-10 |
| CA3048347A1 (en) | 2018-07-12 |
| JP2022176250A (ja) | 2022-11-25 |
| AU2018205730B2 (en) | 2024-05-30 |
| EA201991302A1 (ru) | 2019-11-29 |
| WO2018127570A1 (en) | 2018-07-12 |
| IL267775B1 (en) | 2026-06-01 |
| IL267775A (en) | 2019-09-26 |
| EP3565837A1 (en) | 2019-11-13 |
| US20190315852A1 (en) | 2019-10-17 |
| AU2018205730A1 (en) | 2019-07-11 |
| JP2020503359A (ja) | 2020-01-30 |
| US12162932B2 (en) | 2024-12-10 |
| CN110291105A (zh) | 2019-09-27 |
| EA039433B1 (ru) | 2022-01-27 |
| CN110291105B (zh) | 2024-03-01 |
| KR102679324B1 (ko) | 2024-06-28 |
| US20250002572A1 (en) | 2025-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12187798B2 (en) | LAG-3 binding members | |
| JP2023126946A (ja) | 抗lag-3抗体、pd-1経路阻害剤および免疫療法剤の組み合わせを含む組成物 | |
| US20210115123A1 (en) | Trispecific inhibitors for cancer treatment | |
| KR102777244B1 (ko) | 암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제 | |
| JP7284557B2 (ja) | 医薬組成物 | |
| JP7754506B2 (ja) | ポリオウイルス受容体(pvr)に対する抗体およびその使用 | |
| US20250002572A1 (en) | Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs | |
| CA3043656A1 (en) | Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof | |
| EP3091998A1 (en) | Humanized or chimeric cd3 antibodies | |
| JP2020511481A (ja) | 固形及び血液癌の治療のための併用療法 | |
| JP2023554422A (ja) | がんの治療のための多重特異性抗体 | |
| TWI790193B (zh) | 調控免疫反應之方法及抗體 | |
| CA3155172A1 (en) | Combination of anti-garp antibody and immunomodulator | |
| TW202528358A (zh) | 利用結合至epcam及cd137之藥劑與pd-1軸結合拮抗劑組合的治療方法 | |
| EA045980B1 (ru) | Антитела против рецептора полиовируса (pvr) и их применение | |
| CN118339183A (zh) | 组合中针对pd-l1和cd137的多特异性结合剂 | |
| EA051733B1 (ru) | Композиции, содержащие комбинацию анти-lag-3 антитела, ингибитора сигнального пути pd-1 и иммунотерапевтического средства |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190905 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201216 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211115 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220214 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20220512 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220719 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220922 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220922 |
|
| C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20221017 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20221124 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20221128 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20221219 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230112 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7211952 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |